Acute Kidney Injury
Conditions
Brief summary
Randomized study to evaluate the efficacy and safety of nafamostat mesilate use during continuous renal replacement therapy in acute kidney injury patients at a high risk of bleeding.
Detailed description
Patients were randomly assigned to the nafamostat mesilate (NM) group or the no anticoagulant (NA) group. In patients assigned to the NM group, NM (20mg/h) was used for maintenance anticoagulation. Whereas, in patients assigned to the NA group, normal saline (2mL/h) was infused for continuous renal replacement therapy.
Interventions
nafamostat mesilate use for anticoagulation
DRUGNormal saline
Sponsors
Kyungpook National University Hospital
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients who were admitted to the intensive care unit and required CRRT 1. active bleeding such as gastrointestinal bleeding and intracranial hemorrhage, 2. activated partial thromboplastin time \> 60 s, 3. prothrombin time-international normalized ratio \> 2.0, 4. thrombocytopenia (\<100,000/µL), and 5. surgery within 48 h before CRRT.
Exclusion criteria
* Pregnant or possibly pregnant women * Patients who were allergic to nafamostat mesilate * Patients who were hypercoagulable
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Number of filters used per hour | 24 months |
Secondary
| Measure | Time frame |
|---|---|
| Urea reduction ratio | 24 months |
| Survival rate | 24 months |
Outcome results
None listed